FSP Trends Report

In the increasingly demanding realm of clinical research, where trials are becoming more intricate, drug developers are under mounting pressure to ensure the timely and cost-effective execution of studies, thus expediting therapeutic advancements.

The 2024 FSP Trends Report from the PPD™ clinical research division of Thermo Fisher Scientific delves into the burgeoning adoption of functional service provider (FSP) arrangements as a means to navigate the complexities and hurdles of the pharmaceutical landscape. FSP arrangements have emerged as a vital tactic for biotech and biopharma enterprises to tap into supplementary expertise and resource adaptability necessary for meeting project timelines.

Moreover, innovative providers are introducing new, globally-oriented FSP strategies aimed at keeping their clientele at the forefront of industry evolution. This report delves into various aspects including the current utilization and anticipated growth trajectory of FSPs in clinical research, the forthcoming trends in FSP strategies and models, and the essential components for effectively harnessing an FSP model to drive punctual and cost-efficient project delivery.